MEB Stock Chart & Stats
€23.72
€0.50(2.03%)
At close: 4:00 PM EDT
€23.72
€0.50(2.03%)
Day’s Range― - ―
52-Week Range€19.01 - €37.82
Previous CloseN/A
Volume0.00
Average Volume (3M)7.00
Market Cap
€781.63M
Enterprise Value€731.65
Total Cash (Recent Filing)€84.82M
Total Debt (Recent Filing)€57.41M
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Dec 08, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.91
Shares Outstanding35,924,610
10 Day Avg. Volume0
30 Day Avg. Volume7
Financial Highlights & Ratios
PEG Ratio-0.68
Price to Book (P/B)264.15
Price to Sales (P/S)41.46
P/FCF Ratio-30.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€38.00Price Target Upside60.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.02
Revenue Forecast (FY)€47.65M
Bulls Say, Bears Say
Bulls Say
UZEDY Commercial MomentumRapid UZEDY sales growth is translating into rising royalties, strengthening MedinCell’s recurring revenue base. Continued adoption by Teva can improve cash generation and demonstrate the commercial value of the company’s long-acting injectable platform over the coming quarters.
Royalty Revenue MixA higher royalty share makes revenue more recurring and less dependent on sporadic milestone receipts. This mix shift can improve the quality and predictability of future income as partnered products mature, even though overall earnings remain exposed to development timing.
Pipeline And Platform ExpansionThe broad formulation pipeline provides multiple opportunities to convert BEPO technology into future partnered products and royalties. Partner-funded work also supports external validation and can diversify growth beyond UZEDY, reducing reliance on a single commercial program over time.
Bears Say
Persistent LossesDeepening losses show that revenue growth has not yet produced operating leverage, leaving the business reliant on future product launches, milestones, or financing. Continued investment may be strategically justified, but prolonged negative margins could constrain flexibility if commercialization takes longer.
Cash Burn And Capital SensitivityThe return to substantial cash consumption increases dependence on available liquidity and future monetization progress. Although debt is reported at zero, ongoing burn and thin equity leave less room to absorb delays, fund expanded development, or sustain investment without additional capital.
Partner Execution DependenceMedinCell’s partnered model gives collaborators significant influence over commercialization, launch timing, and development decisions. Strong technology outcomes may therefore translate into revenue more slowly if partners remain conservative, delay programs, or execute below management expectations.
MedinCell SA News
MEB FAQ
What was MedinCell SA’s price range in the past 12 months?
MedinCell SA lowest stock price was €19.01 and its highest was €37.82 in the past 12 months.
What is MedinCell SA’s market cap?
MedinCell SA’s market cap is €781.63M.
When is MedinCell SA’s upcoming earnings report date?
MedinCell SA’s upcoming earnings report date is Dec 08, 2026 which is in 84 days.
How were MedinCell SA’s earnings last quarter?
MedinCell SA released its earnings results on Jun 16, 2026. The company reported -€0.45 earnings per share for the quarter, missing the consensus estimate of -€0.14 by -€0.31.
Is MedinCell SA overvalued?
According to Wall Street analysts MedinCell SA’s price is currently Undervalued.
Does MedinCell SA pay dividends?
MedinCell SA does not currently pay dividends.
What is MedinCell SA’s EPS estimate?
MedinCell SA’s EPS estimate is -0.22.
How many shares outstanding does MedinCell SA have?
MedinCell SA has 35,924,610 shares outstanding.
What happened to MedinCell SA’s price movement after its last earnings report?
MedinCell SA reported an EPS of -€0.45 in its last earnings report, missing expectations of -€0.14. Following the earnings report the stock price went down -0.443%.
Which hedge fund is a major shareholder of MedinCell SA?
Currently, no hedge funds are holding shares in DE:MEB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MedinCell SA
MedinCell S.A. specializes in pioneering diverse therapeutic treatments. At the core of its development lies BEPO, a cutting-edge technology that enables the creation of long-acting injectable pharmaceutical products. This system leverages a unique combination of proprietary copolymers and a biocompatible solvent to effectively dissolve or suspend active drug compounds. The company's advanced pipeline includes several key products: mdc-IRM, a subcutaneous injection currently in Phase III clinical trials for the treatment of schizophrenia; mdc-CWM, an intra-articular injection designed to address pain and inflammation; and mdc-TJK, another subcutaneous injection targeting schizophrenia, presently in preclinical development. MedinCell is also actively engaged in formulation research for additional product candidates. These encompass subcutaneous injections such as mdc-WWM for contraception, mdc-ANG for central nervous system-related conditions, mdc-ELK for depression, and mdc-GRT for organ transplant applications. Furthermore, the firm is investigating perineural injections like mdc-CMV for anesthesia and pain management, and mdc-NVA, also intended for pain relief. MedinCell S.A. maintains its headquarters in Jacou, France.
MEB Stock 12 Month Forecast
Average Price Target
€38.00
▲(60.20% Upside)